Charles S. Berkman

2018 - Ligand Pharmaceuticals

In 2018, Charles S. Berkman earned a total compensation of $1.7M as Senior Vice President and General Counsel at Ligand Pharmaceuticals, a 16% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$177,100
Option Awards$533,547
Salary$402,500
Stock Awards$623,961
Other$6,471
Total$1,743,579

Berkman received $624K in stock awards, accounting for 36% of the total pay in 2018.

Berkman also received $177.1K in non-equity incentive plan, $533.5K in option awards, $402.5K in salary and $6.5K in other compensation.

Rankings

In 2018, Charles S. Berkman's compensation ranked 6,416th out of 14,244 executives tracked by ExecPay. In other words, Berkman earned more than 55.0% of executives.

ClassificationRankingPercentile
All
6,416
out of 14,244
55th
Division
Manufacturing
2,451
out of 5,759
57th
Major group
Chemicals And Allied Products
912
out of 2,122
57th
Industry group
Drugs
766
out of 1,811
58th
Industry
Pharmaceutical Preparations
594
out of 1,385
57th
Source: SEC filing on April 24, 2020.

Berkman's colleagues

We found three more compensation records of executives who worked with Charles S. Berkman at Ligand Pharmaceuticals in 2018.

2018

John Higgins

Ligand Pharmaceuticals

Chief Executive Officer

2018

Matthew Foehr

Ligand Pharmaceuticals

Chief Operating Officer

2018

Matthew Korenberg

Ligand Pharmaceuticals

Chief Financial Officer

News

You may also like